Business Daily Media

Men's Weekly

.

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

  • Written by PR Newswire
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders." He will also present a company update and participate in investor and business development meetings.

The program for the 6th Annual NIF is designed to cover the latest developments in global bio-partnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech and digital therapeutics.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.[1]

 Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-the-sachs-associates-6th-annual-neuroscience-innovation-forum-301712033.html[2]

Read more https://www.prnasia.com/story/archive/3976287_CN76287_0

Why it’s time telcos rethink location and put customer experience first

Maurice Zicman, Vice President - CX Strategy at TP in Australia unpacks why the telco industry must rethink old assumptions and focus on digital-f...

Manny Shah: Is your business disappearing from Google? You’re not alone

Small business owners across Australia are panicking as their websites vanish from Google’s front pages overnight. According to Manny Shah, cofounde...

MR Roads named Queensland Finalist in the 2025 Telstra Best of Business Awards

MR Roads, co-founded by Daniel Mikus and James Rolph, has been announced as a Queensland finalist in the prestigious 2025 Telstra Best of Business...

AWS research shows strong AI adoption momentum in Australia, with startups outpacing large enterprises in innovation

Amazon Web Services (AWS), an Amazon.com company, released new research revealing that while artificial intelligence (AI) adoption continues to acce...

Changing the World One Bite At a Time: IKU Turns 40

One of Australia’s first plant-based, chef-led eateries and now ready meal provider IKU is celebrating its 40 year anniversary with the business e...

Three generations marking 45 years in hot-air balloons

Australia’s leading hot-air balloon company is celebrating 45 years in the sky and its 700,000th passenger, driven by the passion of father-son du...

Sell by LayBy